| Item type |
文献 / Documents(1) |
| 公開日 |
2017-11-28 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Chemoprevention of colorectal cancer : experimental and clinical aspects |
|
言語 |
en |
| 著者 |
高山, 哲治
郷司, 敬洋
谷口, 達哉
イノウエ, アツシ
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Colorectal cancer is a leading cause of cancer-related mortality worldwide. Therefore, an appropriate prevention strategy should be urgently established. Chemoprevention involves the use of oral agents to suppress the development of cancer. Recent progress in the molecular analysis of colorectal cancer has revealed many candidate molecules for chemoprevention. Many new agents targeting these molecules have also been developed. These agents are largely classified into three categories : 1) Signal transduction modulators including epidermal growth factor (EGF) receptor inhibitors, anti-vascular endothelial growth factor (VEGF) antibodies, and inhibitors of oncogene products. 2) Epigenetic modulators including peroxisome proliferative activated receptor (PPAR)-γ agonists, estrogen receptor (ER)-β , and histone deacetylase inhibitors. 3) Anti-inflammatory modulators including cyclooxygenase (COX)-2, EP 1-4, and NF-kB. Of these agents, some actually proceeded to human clinical trials, and have been shown to be active chemopreventive agents. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
colorectal cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
chemoprevention |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
aberrant crypt foci |
| 書誌情報 |
en : The journal of medical investigation : JMI
巻 56,
号 1-2,
p. 1-5,
発行日 2009-02
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13431420 |
| 収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11166929 |
| EID |
|
|
識別子 |
195394 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
jmi_56_1-2_1.pdf (526 KB)
